Join the Truvada group to help and get support from people like you.
Truvada News
High Number of People on HIV-Preventing PrEP Stop Using It
TUESDAY, March 5, 2024 – Many people protected by drugs that prevent HIV infection quit using them, upping their vulnerability to the virus that causes AIDS, new research shows. The drug combo known...
Increase in Out-of-Pocket Costs Could Increase Abandonment of HIV PrEP Meds
MONDAY, Jan. 8, 2024 – An increase in out-of-pocket costs for HIV preexposure prophylaxis (PrEP) medications could increase abandonment of PrEP, leading to an increase in HIV diagnoses, according to...
Court Ruling Could Bring Higher Patient Costs for PrEP, and More HIV Infections
TUESDAY, Jan. 9, 2024 – HIV pre-exposure prophylaxis (PrEP) is a lifeline for Americans, many of them gay men, who are at high risk of contracting the virus that causes AIDS. But a case that is...
2014 to 2021 Saw Increase in HIV Testing, PrEP in Transgender Persons
MONDAY, Dec. 18, 2023 – From 2014 to 2021, there was an increase in the number of transgender persons with an HIV test and who received preexposure prophylaxis (PrEP), according to a study published...
2018 to 2021 Saw Increase in HIV PrEP Provision for Adolescents
MONDAY, Oct. 30, 2023 – From 2018 to 2021, there was an increase in HIV preexposure prophylaxis (PrEP) provision among adolescents, especially among male and older adolescents, according to a study...
Daily Oral PrEP Has Highest Preference Ranking Among Young Men
THURSDAY, Oct. 12, 2023 – Daily oral preexposure prophylaxis (PrEP) has the highest preference ranking among young men who have sex with men, according to a study recently published in the Journal...
Despite New Long-Term Options, People Still Prefer Daily PrEP Pill to Prevent HIV
TUESDAY, Oct. 3, 2023 – New ways to deliver drugs that prevent infection with HIV are out there, but many people still prefer the standard daily PrEP pill, a new study shows. “The oral pill is very e...
Beauty Salon-Based Intervention Builds Knowledge of PrEP in Black Women
THURSDAY, Sept. 14, 2023 – A beauty salon-based intervention improves awareness of and trust in preexposure prophylaxis (PrEP) against HIV among Black cisgender women, according to a study published...
Hypertension, Statin Use Increased for Individuals Using TAF for PrEP
THURSDAY, Sept. 14, 2023 – For individuals taking preexposure prophylaxis (PrEP) for preventing HIV infection, tenofovir alafenamide fumarate (TAF) use is associated with higher incident...
USPSTF Reaffirms Recommendation of PrEP for Those at Increased HIV Risk
TUESDAY, Aug. 22, 2023 – The U.S. Preventive Services Task Force (USPSTF) recommends prescription of preexposure prophylaxis (PrEP) with effective antiretroviral therapy for individuals at increased...
Long-Acting ART Achieves Virologic Suppression for People With HIV
WEDNESDAY, July 5, 2023 – Long-acting antiretroviral therapy (LA-ART) can achieve virologic suppression among people with HIV (PWH), including those with viremia, according to a study published...
PrEP Implant That Protects Against HIV Could Be Near
THURSDAY, June 29, 2023 – Animal research is pointing toward a new way to prevent HIV infection: a refillable implant that continuously delivers antiretroviral medications for up to 20 months at a...
Africa's Contribution to HIV Research Low Relative to Its Burden
MONDAY, June 26, 2023 – Africa's contribution to global HIV research is relatively low compared to its burden of infection, according to a study published online June 22 in PLOS Global Public...
FDA Approves Descovy (emtricitabine and tenofovir alafenamide) for HIV Pre-Exposure Prophylaxis (PrEP)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 3, 2019-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a pre-exposure prophylaxis (PrEP) in...
FDA Approves Expanded Indication for Truvada (emtricitabine and tenofovir disoproxil fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents
FOSTER CITY, Calif.--(BUSINESS WIRE)--May 15, 2018-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Pre-Exposure Prophylaxis, HIV Infection